Verrica Pharmaceuticals Inc. Long-Term Debt, Maturity, Year Five
Verrica Pharmaceuticals Inc. (VRCA) had Long-Term Debt, Maturity, Year Five of $4.38 million as of 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2020-05-07
- 2020-03-31: Long-Term Debt, Maturity, Year Five $4.38M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2020-03-31 | $4.38M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |